Kyverna swaps CEOs, leaning on Kite veterans to lead ‘next chapter’

Warner Biddle and Christi Shaw, two prominent former executives at Gilead’s CAR-T division, will try to turn around an autoimmune cell therapy developer that’s lost most of its value since raising $319 million in a February IPO.